Athira Pharma (NASDAQ:ATHA) Lowered to “Neutral” at BTIG Research

BTIG Research lowered shares of Athira Pharma (NASDAQ:ATHA) from a buy rating to a neutral rating in a research report released on Wednesday morning, MarketBeat reports.

Several other research analysts have also commented on the stock. JMP Securities lowered shares of Athira Pharma from an outperform rating to a market perform rating in a research note on Wednesday. Rodman & Renshaw assumed coverage on shares of Athira Pharma in a research report on Monday, August 19th. They set a buy rating and a $22.00 target price on the stock.

Athira Pharma Price Performance

Shares of ATHA stock opened at $0.54 on Wednesday. Athira Pharma has a fifty-two week low of $0.52 and a fifty-two week high of $4.30. The stock’s 50-day moving average is $2.97 and its two-hundred day moving average is $2.74. The firm has a market cap of $20.75 million, a P/E ratio of -0.18 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. As a group, research analysts expect that Athira Pharma will post -2.56 EPS for the current year.

Insider Buying and Selling

In related news, Director Kelly A. Romano purchased 27,400 shares of the stock in a transaction on Monday, June 24th. The shares were bought at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the acquisition, the director now directly owns 80,715 shares in the company, valued at approximately $195,330.30. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Kelly A. Romano acquired 27,400 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at $195,330.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Romano bought 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the acquisition, the director now directly owns 53,315 shares in the company, valued at $120,491.90. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 8,829 shares of company stock worth $5,033. 19.80% of the stock is currently owned by insiders.

Institutional Trading of Athira Pharma

Several hedge funds have recently added to or reduced their stakes in the business. American Century Companies Inc. increased its position in Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after buying an additional 3,333 shares during the period. Forefront Analytics LLC grew its stake in shares of Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after acquiring an additional 8,955 shares during the last quarter. Renaissance Technologies LLC increased its position in Athira Pharma by 3.5% during the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares during the period. Rothschild Investment LLC bought a new position in Athira Pharma during the second quarter worth $34,000. Finally, Private Advisor Group LLC acquired a new position in Athira Pharma during the 4th quarter valued at $32,000. Institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.